CureVac NV

CVAC · NASDAQ

$4.66−$0.01 (−0.21%)TodayMarket closed · Jan 5, 4:00 PM ET

No price history for this range.

Latest news

Press releaseDec 18, 4:45 AM ETGlobe Newswire
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
Press releaseDec 3, 9:01 AM ETGlobe Newswire
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
Press releaseNov 26, 7:30 AM ETGlobe Newswire
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
Press releaseNov 25, 7:05 PM ETACCESS Newswire
CureVac Announces Voting Results of Extraordinary General Meeting
NewsNov 24, 9:47 AM ETAvi Kapoor
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
NewsNov 24, 8:18 AM ET
CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate
Press releaseNov 24, 7:30 AM ETACCESS Newswire
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
NewsOct 22, 6:51 AM ET
BioNTech Commences Public Exchange Offer For All Outstanding Shares Of CureVac; CureVac Shareholders Receive ~$5.46 In BioNTech ADSs For Each CureVac Share
Press releaseOct 22, 6:45 AM ETGlobe Newswire
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
Press releaseAug 15, 7:50 AM ETACCESS Newswire
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
NewsAug 8, 5:42 AM ET
Curevac And GSK Have Agreed To Resolve And Dismiss All Pending Patent Litigation In The US With BioNTech And Pfizer, Related To mRNA-Based COVID-19 Vaccines, CureVac and GSK Will Receive $740M And Single-Digit Royalties
NewsAug 4, 10:32 AM ETVandana Singh
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
Press releaseJun 24, 4:35 PM ETACCESS Newswire
CureVac Announces Voting Results of General Meeting
NewsJun 16, 3:06 PM ET
5 Stocks To Ride The German Market Rally
Press releaseJun 12, 2:30 PM ETPRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders
NewsJun 12, 12:07 PM ETAvi Kapoor
Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Results
NewsJun 12, 11:07 AM ETVandana Singh
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
Press releaseJun 12, 8:39 AM ETBusiness Wire
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
NewsMay 20, 3:42 PM ETHenry Khederian
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction
Press releaseMay 15, 4:45 PM ETACCESS Newswire
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Press releaseApr 10, 7:30 AM ETACCESS Newswire
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
NewsApr 10, 4:32 AM ET
Earnings Scheduled For April 10, 2025
NewsApr 9, 10:01 AM ET
Insights Ahead: CureVac's Quarterly Earnings
NewsMar 28, 8:58 AM ETVandana Singh
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
NewsMar 28, 7:21 AM ET
Market-Moving News for March 28th
Press releaseMar 27, 4:30 PM ETACCESS Newswire
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
NewsFeb 12, 5:35 PM ETErica Kollmann
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED)
NewsJan 21, 6:27 PM ETErica Kollmann
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
NewsJan 10, 11:16 AM ETHenry Khederian
Why CureVac (CVAC) Shares Are Volatile
NewsJan 8, 1:39 PM ETHenry Khederian
Why CureVac (CVAC) Stock Is Moving
NewsJan 8, 12:54 PM ETChandrima Sanyal
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
NewsJan 7, 11:56 AM ETErica Kollmann
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Press releaseNov 12, 7:20 AM ETACCESSWIRE
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Press releaseJul 11, 7:15 AM ETACCESSWIRE
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Press releaseJul 11, 7:00 AM ETBusiness Wire
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

CureVac Announces Voting Results of Extraordinary General Meeting

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

CureVac Q3 EPS $1.41 Beats $(0.17) Estimate, Sales $63.295M Beat $14.520M Estimate

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

BioNTech Commences Public Exchange Offer For All Outstanding Shares Of CureVac; CureVac Shareholders Receive ~$5.46 In BioNTech ADSs For Each CureVac Share

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

Curevac And GSK Have Agreed To Resolve And Dismiss All Pending Patent Litigation In The US With BioNTech And Pfizer, Related To mRNA-Based COVID-19 Vaccines, CureVac and GSK Will Receive $740M And Single-Digit Royalties

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

CureVac Announces Voting Results of General Meeting

5 Stocks To Ride The German Market Rally

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, SOAR, MTWO on Behalf of Shareholders

Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Results

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders

CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Earnings Scheduled For April 10, 2025

Insights Ahead: CureVac's Quarterly Earnings

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

Market-Moving News for March 28th

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED)

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine

Why CureVac (CVAC) Shares Are Volatile

Why CureVac (CVAC) Stock Is Moving

Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer